Skip to main content
SpringerLink
Log in

Effect of Selective Serotonin Reuptake Inhibitors on Platelet Activation

Can They Prevent Acute Myocardial Infarction?

  • Current Opinion
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

In recent years a large body of evidence from several longitudinal studies has emerged suggesting that depression is an independent risk factor for cardiovascular disease (CVD) and that the association between depression and increased CVD risk is not merely due to negative mood-driven behavior related with depression. Even though the underlying mechanisms are not well understood, several hypotheses and explanations have been proposed such as increased activation of the hypothalamic-pituitary-adrenal axis, abnormalities in the sympathoadrenal system, or abnormalities in platelet function. Platelet function abnormalities, including increased platelet reactivity, may predispose patients with depressive disorders to clotting diatheses and may explain their vulnerability to CVD.

Serotonin secreted by platelets induces both platelet aggregation and coronary vasoconstriction. Even though serotonin itself is only a weak platelet agonist, it markedly enhances platelet reactions to a variety of other agonists. Several studies have shown that selective serotonin reuptake inhibitors (SSRIs) reduce platelet and whole blood serotonin concentrations after repeated doses, and could therefore exert an inhibitory effect on platelet activation. For that reason, it was hypothesized that SSRIs could have a protective effect against myocardial infarction (MI).

Results from three currently available epidemiological studies assessing the risk of MI in patients treated with antidepressants, including SSRIs, are controversial with respect to a potential beneficial effect of SSRIs on CVD risk in depressed patients. However, there is evidence that exposure to SSRIs does not substantially increase the risk of CVD in patients. A recent randomized, double-blind, placebo-controlled, multicenter trial that evaluated the safety and efficacy of the SSRI sertraline in patients with major depression and acute MI or unstable angina suggested that sertraline is well tolerated and effective. Further epidemiological studies or longer-term clinical trials may shed more light on this issue, and answer the question conclusively, whether the effect of SSRIs on platelets or another mechanism translates into a decreased risk of CVD in depressed patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I

Similar content being viewed by others

References

  1. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55(7): 580–92

    Article  PubMed  CAS  Google Scholar 

  2. Jiang W, Krishnan RR, O’Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002; 16(2): 111–27

    Article  PubMed  Google Scholar 

  3. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99(16): 2192–217

    Article  PubMed  CAS  Google Scholar 

  4. Hayward C. Psychiatric illness and cardiovascular disease risk. Epidemiol Rev 1995; 17(1): 129–38

    PubMed  CAS  Google Scholar 

  5. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108(1): 2–8

    Article  PubMed  CAS  Google Scholar 

  6. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59 Suppl. 15: 42–8

    PubMed  CAS  Google Scholar 

  7. Rickels K, Schweizer E. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51 Suppl. B: 9–12

    PubMed  Google Scholar 

  8. Kasper S, Fuger J, Moller HJ. Comparative efficacy of antidepressants. Drugs 1992; 43 Suppl. 2: 11–22

    Article  PubMed  Google Scholar 

  9. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58(1): 19–36

    Article  PubMed  CAS  Google Scholar 

  10. Celada P, Dolera M, Alvarez E, et al. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients: relationship to clinical improvement. J Affect Disord 1992; 25(4): 243–50

    Article  PubMed  CAS  Google Scholar 

  11. Menys VC, Smith CCT, Lewins P, et al. Platelet5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci 1996; 91(1): 87–92

    PubMed  CAS  Google Scholar 

  12. Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68(4): 435–42

    Article  PubMed  CAS  Google Scholar 

  13. De Clerck F. The role of serotonin in thrombogenesis. Clin Physiol Biochem 1990; 8 Suppl. 3: 40–9

    PubMed  Google Scholar 

  14. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37(1): 12–6

    Article  PubMed  CAS  Google Scholar 

  15. Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother 1992; 26(12): 1517–9

    PubMed  CAS  Google Scholar 

  16. Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine [letter]. Am J Psychiatry 1992; 149(3): 412

    PubMed  CAS  Google Scholar 

  17. Cooper TA, Valcour VG, Gibbons RB, et al. Spontaneous ecchymoses due to paroxetine administration. Am J Med 1998; 104(2): 197–8

    Article  PubMed  CAS  Google Scholar 

  18. Evans TG, Buys SS, Rodgers GM. Acquired abnormalities in platelet function [letter]. N Engl J Med 1991; 324(23): 1671

    Google Scholar 

  19. Gunzberger DW, Martinez D. Adverse vascular effects associated with fluoxetine [letter]. Am J Psychiatry 1992; 149(12): 1751

    PubMed  CAS  Google Scholar 

  20. Humphries JE, Wheby MS, Vanden Berg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990; 114(7): 727–8

    PubMed  CAS  Google Scholar 

  21. Ottervanger JP, Stricker BHC, Huls J, et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry 1994; 151(5): 781–2

    PubMed  CAS  Google Scholar 

  22. Shader RI, Greenblatt DJ. Selective serotonin reuptake inhibitor antidepressants: cardiovascular complications: sorting through findings. J Clin Psychopharmacol 2001; 21(5): 467–8

    Article  PubMed  CAS  Google Scholar 

  23. Zarzar MN, Kingsley RS. Use of fluoxetine in a person with cardiac arrhythmias. Psychosomatics 1990; 31(2): 235–6

    Article  PubMed  CAS  Google Scholar 

  24. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51(9): 385–6

    PubMed  CAS  Google Scholar 

  25. Buff DD, Brenner R, Kirtane SS, et al. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52(4): 174–6

    PubMed  CAS  Google Scholar 

  26. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23(4): 435–40

    Article  Google Scholar 

  27. Shapiro PA, Lesperance F, Frasure-Smith N, et al. An open-label preliminary trial of sertraline treatment of major depression after acute myocardial infarction (the SADHAT trssial). Sertraline Anti-Depressant Heart Attack trial. Am Heart J 1999; 137(6): 1100–6

    Article  PubMed  CAS  Google Scholar 

  28. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279(4): 287–91

    Article  PubMed  CAS  Google Scholar 

  29. Strik JJ, Honig A, Lousberg R, et al. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients. Int Clin Psychopharmacol 1998; 13(6): 263–7

    Article  PubMed  CAS  Google Scholar 

  30. Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000; 62(6): 783–9

    PubMed  CAS  Google Scholar 

  31. Malzberg B. Mortality among patients with involution melancholia. Am J Psychiatry 1937; 93: 1231–8

    Google Scholar 

  32. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155(1): 4–11

    PubMed  CAS  Google Scholar 

  33. Weeke A, Juel K, Vaeth M. Cardiovascular death and manic-depressive psychosis. J Affect Disord 1987; 13(3): 287–92

    Article  PubMed  CAS  Google Scholar 

  34. Hallstrom T, Lapidus L, Bengtsson C, et al. Psychosocial factors and risk of ischaemic heart disease and death in women: a twelve-year follow-up of participants in the population study of women in Gothenburg, Sweden. J Psychosom Res 1986; 30(4): 451–9

    Article  PubMed  CAS  Google Scholar 

  35. Appels A, Mulder P. Excess fatigue as a precursor of myocardial infarction. Eur Heart J 1988; 9(7): 758–64

    PubMed  CAS  Google Scholar 

  36. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology 1993; 4(4): 285–94

    Article  PubMed  CAS  Google Scholar 

  37. Aromaa A, Raitasalo R, Reunanen A, et al. Depression and cardiovascular diseases. Acta Psychiatr Scand Suppl 1994; 377: 77–82

    Article  PubMed  CAS  Google Scholar 

  38. Simonsick EM, Wallace RB, Blazer DG, et al. Depressive symptomatology and hypertension-associated morbidity and mortality in older adults. Psychosom Med 1995; 57(5): 427–35

    PubMed  CAS  Google Scholar 

  39. Everson SA, Goldberg DE, Kaplan GA, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 1996; 58: 113–21

    PubMed  CAS  Google Scholar 

  40. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in depression as a precursor of cardiovascular events: SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Arch Intern Med 1996; 156(5): 553–61

    Article  PubMed  CAS  Google Scholar 

  41. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93(11): 1976–80

    Article  PubMed  CAS  Google Scholar 

  42. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction: prospective data from the Baltimore ECA follow-up. Circulation 1996; 94(12): 3123–9

    Article  PubMed  CAS  Google Scholar 

  43. Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary artery disease in men. Arch Intern Med 1998; 158(13): 1422–6

    Article  PubMed  CAS  Google Scholar 

  44. Mendes de Leon CF, Krumholz HM, Seeman TS, et al. Depression and risk of coronary heart disease in elderly men and women: New Haven EPESE, 1982–1991: established populations for the epidemiologic studies of the elderly. Arch Intern Med 1998; 158(21): 2341–8

    Article  Google Scholar 

  45. Ariyo AA, Haan M, Tangen CM, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans: Cardiovascular Health Study Collaborative Research Group. Circulation 2000; 102(15): 1773–9

    Article  PubMed  CAS  Google Scholar 

  46. Ferketich AK, Schwartzbaum JA, Frid DJ, et al. Depression as an antecedent to heart disease among women and men in the NHANES I study: National Health and Nutrition Examination Survey. Arch Intern Med 2000; 160(9): 1261–8

    Article  PubMed  CAS  Google Scholar 

  47. Penninx BW, Beekman AT, Honig A, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58(3): 221–7

    Article  PubMed  CAS  Google Scholar 

  48. Murphy JM, Monson RR, Olivier DC, et al. Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987; 44(5): 473–80

    Article  PubMed  CAS  Google Scholar 

  49. Vogt T, Pope C, Mullooly J, et al. Mental health status as a predictor of morbidity and mortality: a 15-year follow-up of a health maintenance organization. Am J Public Health 1994; 84(2): 227–31

    Article  PubMed  CAS  Google Scholar 

  50. Kubzansky LD, Kawachi I, Spiro III A, et al. Is worrying bad for your heart?.: a prospective study of worry and coronary heart disease in the Normative Aging Study. Circulation 1997; 95(4): 818–24

    Article  PubMed  CAS  Google Scholar 

  51. Strik JJ, Honig A, Maes M. Depression and myocardial infarction: relationship between heart and mind. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25(4): 879–92

    Article  PubMed  CAS  Google Scholar 

  52. Forrester AW, Lipsey JR, Teitelbaum ML, et al. Depression following myocardial infarction. Int J Psychiatry Med 1992; 22(1): 33–46

    Article  PubMed  CAS  Google Scholar 

  53. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270(15): 1819–25

    Article  PubMed  CAS  Google Scholar 

  54. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91(4): 999–1005

    Article  PubMed  CAS  Google Scholar 

  55. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149(8): 1785–9

    Article  PubMed  CAS  Google Scholar 

  56. Irvine J, Basinski A, Baker B, et al. Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med 1999; 61(6): 729–37

    PubMed  CAS  Google Scholar 

  57. Lane D, Carroll D, Ring C, et al. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001; 63(2): 221–30

    PubMed  CAS  Google Scholar 

  58. Frasure-Smith N, Lesperance F, Juneau M, et al. Gender, depression, and one-year prognosis after myocardial infarction. Psychosom Med 1999; 61(1): 26–37

    PubMed  CAS  Google Scholar 

  59. Ladwig KH, Roll G, Breithardt G, et al. Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet 1994; 343(8888): 20–3

    Article  PubMed  CAS  Google Scholar 

  60. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332(23): 1553–9

    Article  PubMed  CAS  Google Scholar 

  61. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000; 140 (4 Suppl.): 57–62

    Article  PubMed  CAS  Google Scholar 

  62. Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153(10): 1313–7

    PubMed  CAS  Google Scholar 

  63. Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanisms. Psychosom Med 1991; 53(6): 643–68

    PubMed  CAS  Google Scholar 

  64. De Clerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991; 17 Suppl. 5: S1–5

    Article  PubMed  Google Scholar 

  65. Laghrissi-Thode F, Wagner WR, Pollock BG, et al. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; 42(4): 290–5

    Article  PubMed  CAS  Google Scholar 

  66. Lederbogen F, Gilles M, Maras A, et al. Increased platelet aggregability in major depression? Psychiatry Res 2001; 102(3): 255–61

    Article  PubMed  CAS  Google Scholar 

  67. Blardi P, De Lalla A, Leo A, et al. Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. J Clin Psychopharmacol 2002; 22(2): 131–6

    Article  PubMed  CAS  Google Scholar 

  68. Walsh MT, Dinan TG, Condren RM, et al. Depression is associated with an increase in the expression of the platelet adhesion receptor glycoprotein Ib. Life Sci 2002; 70(26): 3155–65

    Article  PubMed  CAS  Google Scholar 

  69. Biegon A, Essar N, Israeli M, et al. Serotonin 5-HT2 receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharmacology 1990; 102(1): 73–5

    Article  PubMed  CAS  Google Scholar 

  70. Biegon A, Weizman A, Karp L, et al. Serotonin 5-HT2 receptor binding on blood platelets: a peripheral marker for depression? Life Sci 1987; 41(22): 2485–92

    Article  PubMed  CAS  Google Scholar 

  71. Arora RC, Meltzer HY. Increased serotonin (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. Life Sci 1989; 44(11): 725–34

    Article  PubMed  CAS  Google Scholar 

  72. Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984; 226(4680): 1342–4

    Article  PubMed  CAS  Google Scholar 

  73. Banki CM, Bissette G, Arato M, et al. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987; 144(7): 873–7

    PubMed  CAS  Google Scholar 

  74. France RD, Urban B, Krishnan KR, et al. CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression. Biol Psychiatry 1988; 23(1): 86–8

    Article  PubMed  CAS  Google Scholar 

  75. Carroll BJ, Curtis GC, Davies BM, et al. Urinary free cortisol excretion in depression. Psychol Med 1976; 6(1): 43–50

    Article  PubMed  CAS  Google Scholar 

  76. Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease: pathophysiologic and diagnostic implications. N Engl J Med 1986; 314(21): 1329–35

    Article  PubMed  CAS  Google Scholar 

  77. Schlechte JA, Coffman T. Plasma free cortisol in depressive illness: a review of findings and clinical implications. Psychiatr Med 1985; 3(1): 23–31

    PubMed  CAS  Google Scholar 

  78. Weber-Hamann B, Hentschel F, Kniest A, et al. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002; 64(2): 274–7

    PubMed  Google Scholar 

  79. Wyatt RJ, Portnoy B, Kupfer DJ, et al. Resting plasma catecholamine concentrations in patients with depression and anxiety. Arch Gen Psychiatry 1971; 24(1): 65–70

    Article  PubMed  CAS  Google Scholar 

  80. Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994; 51(5): 411–22

    Article  PubMed  CAS  Google Scholar 

  81. Anfossi G, Trovati M. Role of catecholamine s in platelet function: pathophysiological and clinical significance. Eur J Clin Invest 1996; 26(5): 353–70

    Article  PubMed  CAS  Google Scholar 

  82. Shores MM, Pascualy M, Lewis NL, et al. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 2001; 26(4): 433–9

    Article  PubMed  CAS  Google Scholar 

  83. Calhoun JW, Calhoun DD. Prolonged bleeding time in a patient treated with sertraline [letter]. Am J Psychiatry 1996; 153: 443

    PubMed  CAS  Google Scholar 

  84. Tielens JA. Vitamin C for paroxetine- and fluvoxamine-associated bleeding. Am J Psychiatry 1997; 154(6): 883–4

    PubMed  CAS  Google Scholar 

  85. Wilmshurst PT, Kumar AV. Subhyaloid haemorrhage with fluoxetine [letter]. Eye 1996; 10 (Pt 1): 141

    Article  PubMed  Google Scholar 

  86. Leung M, Shore R. Fluvoxamine-associated bleeding. Can J Psychiatry 1996; 41(9): 604–5

    PubMed  CAS  Google Scholar 

  87. Mhanna MJ, Bennet II JB, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997; 100(1): 158–9

    Article  PubMed  CAS  Google Scholar 

  88. Yaryura-Tobias JA, Kirschen H, Ninan P, et al. Fluoxetine and bleeding in obsessive-compulsive disorder [letter]. Am J Psychiatry 1991; 148(7): 949

    Google Scholar 

  89. Lake MB, Birmhaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10: 35–8

    Article  PubMed  CAS  Google Scholar 

  90. Berg C, Couturier F, Grass F, et al. Saignements sous inhibiteurs de la recapture de la sérotonine: à propos d’un cas clinique. Therapie 2001; 56(1): 65–7

    Article  PubMed  CAS  Google Scholar 

  91. Nelva A, Guy C, Tardy-Poncet B, et al. Syndrômes hémorragiques sous antidépresseurs inhibiteurs sélectifs de la recapture de la sérotonine (ISRS): a propos de sept cas et revue de la littérature. Rev Med Interne 2000; 21(2): 152–60

    Article  PubMed  CAS  Google Scholar 

  92. Vandel P, Vandel S, Kantelip JP. Saignements et inhibiteurs de la recapture de la sérotonine: à propos de deux cas. Therapie 2001; 56(4): 445–7

    PubMed  CAS  Google Scholar 

  93. de Abajo FJ, Garcia Rodriguez LA, Montera D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319(7217): 1106–9

    Article  PubMed  Google Scholar 

  94. de Abajo F, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol 2000; 50(1): 43–7

    Article  PubMed  Google Scholar 

  95. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33(6): 1465–73

    Article  PubMed  CAS  Google Scholar 

  96. Layton D, Clark DW, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding?.: results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57(2): 167–76

    Article  PubMed  CAS  Google Scholar 

  97. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323(7314): 655–8

    Article  PubMed  Google Scholar 

  98. Markovitz JH, Shuster JL, Chitwood WS, et al. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000; 157(6): 1006–8

    Article  PubMed  CAS  Google Scholar 

  99. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000; 57(9): 875–82

    Article  PubMed  CAS  Google Scholar 

  100. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20(2): 137–40

    Article  PubMed  CAS  Google Scholar 

  101. Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43(5): 453–62

    Article  PubMed  CAS  Google Scholar 

  102. Muck-Seler D, Jakovljevic M, Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Disord 1991; 23(3): 157–64

    Article  PubMed  CAS  Google Scholar 

  103. Javors MA, Houston JP, Tekell JL, et al. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3(3): 229–35

    Article  PubMed  CAS  Google Scholar 

  104. Nair GV, Gurbel PA, O’Connor CM, et al. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am J Cardiol 1999; 84(3): 321–3

    Article  PubMed  CAS  Google Scholar 

  105. Glassman AH, Rodriguez AI, Shapiro PA. The use of antidepressant drugs in patients with heart disease. J Clin Psychiatry 1998; 59 Suppl. 10: 16–21

    PubMed  CAS  Google Scholar 

  106. Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155(5): 660–5

    PubMed  CAS  Google Scholar 

  107. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001; 52(2): 179–84

    Article  PubMed  CAS  Google Scholar 

  108. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104(16): 1894–8

    Article  PubMed  CAS  Google Scholar 

  109. Barefoot JC, Williams RB. Antidepressant use and the risk of myocardial infarction. Am J Med 2000; 108(1): 87–8

    Article  PubMed  CAS  Google Scholar 

  110. Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350(9084): 1097–9

    Article  PubMed  CAS  Google Scholar 

  111. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 1991; 302(6779): 766–8

    Article  PubMed  CAS  Google Scholar 

  112. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992; 1: 347–9

    Article  Google Scholar 

  113. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45(5): 419–25

    Article  Google Scholar 

  114. Kimmel SE, Berlin JA, Miles C, et al. Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001; 37(5): 1297–302

    Article  PubMed  CAS  Google Scholar 

  115. Glassman AH, O’Connor CM, Califf RM. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288(6): 701–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Christoph R. Meier is recipient of a grant from the Swiss National Science Foundation (grant number 32-056 751).

Author information

Authors and Affiliations

  1. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, University Hospital of Basel, Petersgraben 4, CH-4031, Basel, Switzerland

    Raymond G. Schlienger & Christoph R. Meier

  2. Department of Pharmacy, Institute of Clinical Pharmacy, University of Basel, Basel, Switzerland

    Raymond G. Schlienger

  3. Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, Massachusetts, USA

    Christoph R. Meier

Authors
  1. Raymond G. Schlienger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph R. Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raymond G. Schlienger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlienger, R.G., Meier, C.R. Effect of Selective Serotonin Reuptake Inhibitors on Platelet Activation. Am J Cardiovasc Drugs 3, 149–162 (2003). https://doi.org/10.2165/00129784-200303030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200303030-00001

Keywords

Search

Navigation